Whole-body diffusion-weighted magnetic resonance imaging for Peritoneal Carcinomatosis
Phase-Based Progress Estimates
Effectiveness
Safety
CHU de Québec, Quebec City, Canada
Peritoneal Carcinomatosis+8 More
Whole-body diffusion-weighted magnetic resonance imaging - DiagnosticTestEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
Diffusion-weighted magnetic resonance imaging (DWI/MRI) has been described in recent literature as a highly sensitive and specific modality for the detection of peritoneal metastases (PM). It has been demonstrated to be superior to computed tomography (CT) for patients with known peritoneal disease from colorectal and gynaecological malignancies. However, the literature is scarce on the role of DWI/MRI in patients with pancreatic ductal-adenocarcinoma (PDAC). The aim of this study is to prospectively assess the added value of whole-body DWI/MRI (WB-DWI/MRI) to CT for detection of PM in the preoperative staging of patients with high-risk PDAC and evaluate how it correlates with intraoperative findings.
Eligible Conditions
- Peritoneal Carcinomatosis
- Pancreas Cancer, Duct Cell Adenocarcinoma
- Adenocarcinoma
- Neoplasm Metastasis
Treatment Effectiveness
Effectiveness Progress
Other trials for Peritoneal Carcinomatosis
Study Objectives
2 Primary · 1 Secondary · Reporting Duration: 30 months
24 months
Peritoneal findings
Unexpected abortion
30 months
Early distant recurrence
Trial Safety
Safety Progress
Other trials for Peritoneal Carcinomatosis
Trial Design
1 Treatment Group
DWI-MRI
1 of 1
Experimental Treatment
40 Total Participants · 1 Treatment Group
Primary Treatment: Whole-body diffusion-weighted magnetic resonance imaging · No Placebo Group · N/A
DWI-MRI
DiagnosticTest
Experimental Group · 1 Intervention: Whole-body diffusion-weighted magnetic resonance imaging · Intervention Types: DiagnosticTestTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 30 months
Closest Location: CHU de Québec · Quebec City, Canada
2016First Recorded Clinical Trial
1 TrialsResearching Peritoneal Carcinomatosis
12 CompletedClinical Trials
Who is running the clinical trial?
Laval UniversityLead Sponsor
381 Previous Clinical Trials
154,146 Total Patients Enrolled
Alexandre Brind'Amour, MDPrincipal InvestigatorLaval University
Eligibility Criteria
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have a confirmed diagnosis of pancreatic ductal adenocarcinoma.
The CA 19-9 level is ≥ 400 U/mL with normal bilirubin level (< 40).
Patient fit for pancreatic resection (ECOG 0 or 1).
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
References
- Mizrahi, Jonathan D, Rishi Surana, Juan W Valle, and Rachna T Shroff. 2020. “Pancreatic Cancer”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(20)30974-0.
- Mattevi, C., J. Garnier, U. Marchese, J. Ewald, M. Gilabert, F. Poizat, G. Piana, J. R. Delpero, and O. Turrini. 2020. “Has the Non-resection Rate Decreased During the Last Two Decades Among Patients Undergoing Surgical Exploration for Pancreatic Adenocarcinoma?”. BMC Surgery. Springer Science and Business Media LLC. doi:10.1186/s12893-020-00835-3.
- Ryan, David P., Theodore S. Hong, and Nabeel Bardeesy. 2014. “Pancreatic Adenocarcinoma”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmra1404198.
- Brind’Amour, Alexandre, Mitchell Webb, Marina Parapini, Lucas Sidéris, Maja Segedi, Stephen W. Chung, Stéphanie Chartier-Plante, Pierre Dubé, Charles H. Scudamore, and Peter T. W. Kim. 2021. “The Role of Intraperitoneal Chemotherapy in the Surgical Management of Pancreatic Ductal Adenocarcinoma: A Systematic Review”. Clinical & Experimental Metastasis. Springer Science and Business Media LLC. doi:10.1007/s10585-021-10074-2.
- Patel, Chirag M., Anju Sahdev, and Rodney H. Reznek. 2011. “CT, MRI and PET Imaging in Peritoneal Malignancy”. Cancer Imaging. E-MED LTD. doi:10.1102/1470-7330.2011.0016.
- Paracha, Munizay, Kathryn Van Orden, Gregory Patts, Jennifer Tseng, David McAneny, and Teviah Sachs. 2018. “Opportunity Lost? Diagnostic Laparoscopy in Patients with Pancreatic Cancer in the National Surgical Quality Improvement Program Database”. World Journal of Surgery. Springer Science and Business Media LLC. doi:10.1007/s00268-018-4855-8.
- Allen VB, Gurusamy KS, Takwoingi Y, Kalia A, Davidson BR. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev. 2016 Jul 6;7:CD009323. doi: 10.1002/14651858.CD009323.pub3. Review.
- HISHINUMA, S, Y OGATA, M TOMIKAWA, I OZAWA, K HIRABAYASHI, and S IGARASHI. 2006. “Patterns of Recurrence After Curative Resection of Pancreatic Cancer, Based on Autopsy Findings”. Journal of Gastrointestinal Surgery. Elsevier BV. doi:10.1016/j.gassur.2005.09.016.
- De Vuysere, Sofie, Vincent Vandecaveye, Yves De Bruecker, Saskia Carton, Koen Vermeiren, Tim Tollens, Frederik De Keyzer, and Raphaëla Carmen Dresen. 2021. “Accuracy of Whole-body Diffusion-weighted MRI (WB-DWI/MRI) in Diagnosis, Staging and Follow-up of Gastric Cancer, in Comparison to CT: A Pilot Study”. BMC Medical Imaging. Springer Science and Business Media LLC. doi:10.1186/s12880-021-00550-2.
- Bray, Freddie, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L. Siegel, Lindsey A. Torre, and Ahmedin Jemal. 2018. “Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries”. CA: A Cancer Journal for Clinicians. Wiley. doi:10.3322/caac.21492.
- Liu, Xinchun, Yue Fu, Qiuyang Chen, Junli Wu, Wentao Gao, Kuirong Jiang, Yi Miao, and Jishu Wei. 2018. “Predictors of Distant Metastasis on Exploration in Patients with Potentially Resectable Pancreatic Cancer”. BMC Gastroenterology. Springer Science and Business Media LLC. doi:10.1186/s12876-018-0891-y.
- Dresen, Raphaëla Carmen, Sofie De Vuysere, Frederik De Keyzer, Eric Van Cutsem, Hans Prenen, Ragna Vanslembrouck, Gert De Hertogh, Albert Wolthuis, André D’Hoore, and Vincent Vandecaveye. 2019. “Whole-body Diffusion-weighted MRI for Operability Assessment in Patients with Colorectal Cancer and Peritoneal Metastases”. Cancer Imaging. Springer Science and Business Media LLC. doi:10.1186/s40644-018-0187-z.
- Huan, Zhang, Dai Weixing, Fu Caixia, Yan Xu, Stemmer Alto, Tong Tong, and Cai Guoxiang. 2018. “Diagnostic Value of Whole-body MRI with Diffusion-weighted Sequence for Detection of Peritoneal Metastases in Colorectal Malignancy”. Cancer Biology & Medicine. China Anti-cancer Association. doi:10.20892/j.issn.2095-3941.2017.0162.
- Nordby, T., H. Hugenschmidt, M.W. Fagerland, T. Ikdahl, T. Buanes, and K.J. Labori. 2013. “Follow-up After Curative Surgery for Pancreatic Ductal Adenocarcinoma: Asymptomatic Recurrence Is Associated with Improved Survival”. European Journal of Surgical Oncology (EJSO). Elsevier BV. doi:10.1016/j.ejso.2013.02.020.
- Jayakrishnan, Thejus T, Anthony J Zacharias, Avishkar Sharma, Sam G Pappas, T Clark Gamblin, and Kiran K Turaga. 2014. “Role of Laparoscopy in Patients with Peritoneal Metastases Considered for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)”. World Journal of Surgical Oncology. Springer Science and Business Media LLC. doi:10.1186/1477-7819-12-270.
- Namimoto, Tomohiro, Kazuo Awai, Takeshi Nakaura, Yumi Yanaga, Toshinori Hirai, and Yasuyuki Yamashita. 2008. “Role of Diffusion-weighted Imaging in the Diagnosis of Gynecological Diseases”. European Radiology. Springer Science and Business Media LLC. doi:10.1007/s00330-008-1185-5.
- De Rosa, Antonella, Iain C. Cameron, and Dhanwant Gomez. 2016. “Indications for Staging Laparoscopy in Pancreatic Cancer”. Hpb. Elsevier BV. doi:10.1016/j.hpb.2015.10.004.
- Vasilyeva, Elizaveta, Jennifer Li, Sameer Desai, Stephen W. Chung, Charles H. Scudamore, Maja Segedi, and Peter TW Kim. 2020. “Impact of Surgical Wait Times on Oncologic Outcomes in Resectable Pancreas Adenocarcinoma”. Hpb. Elsevier BV. doi:10.1016/j.hpb.2019.10.013.
- Dong, Li, Kuo Li, and Taisong Peng. 2021. “Diagnostic Value of Diffusion-weighted Imaging/magnetic Resonance Imaging for Peritoneal Metastasis from Malignant Tumor”. Medicine. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/md.0000000000024251.
- Alexandre Brind'Amour 2022. "Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05340569.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments